ARWR - Arrowhead Pharmaceuticals Inc
NYSE * Health Care * Biotechnology
$70.53
+$0.40 (+0.57%)
About Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
ARWR Key Statistics
Market Cap
$9.82B
P/E Ratio
43.83
P/B Ratio
18.13
EPS
$1.60
Revenue Growth
+104.6%
Profit Margin
0.2%
Employees
711
How ARWR Compares to Peers
P/E Rank
#6
of 6
Margin Rank
#5
of 6
Growth Rank
#1
of 6
Size Rank
#6
of 6
Arrowhead Pharmaceuticals Inc Company Information
- Headquarters
- California; U.S.A
- Website
- arrowheadpharma.com
- Sector
- Health Care
- Industry
- Biotechnology